WST$269.958
Chart
Performance
Key Stats
AI WST Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyWest Pharmaceutical Services demonstrates solid fundamental strength and positive long-term market positioning, with recent price action showing significant upward momentum. Investors should monitor short-term technical indicators for potential entry points.
Thematic
West Pharmaceutical Services is well-positioned within the healthcare sector, benefiting from trends in biologics, advanced drug delivery, and a growing demand for high-quality pharmaceutical packaging solutions.
Fundamental
West Pharmaceutical Services exhibits strong profitability, healthy cash flow generation, and a robust balance sheet, with consistent earnings performance and manageable debt levels.
Technical
The stock has experienced a significant upward price movement recently, with strong momentum indicated by moving averages and oscillators. However, some indicators suggest it may be approaching overbought territory.
| Factor | Score |
|---|---|
| Biologics Growth | 85 |
| Drug Delivery Innovation | 88 |
| Healthcare Spending Trends | 75 |
| Supply Chain Resilience | 70 |
| Regulatory Landscape (Pharma Packaging) | 72 |
| Factor | Score |
|---|---|
| Valuation | 55 |
| Profitability | 80 |
| Growth | 65 |
| Balance Sheet Health | 95 |
| Cash Flow | 85 |
| Dividend | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 70 |
| Volume Confirmation | 75 |
| Short-Term Indicators | 75 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
The company has exceeded EPS estimates in 9 out of the last 12 reported quarters, with an average surprise of +11.12%. This demonstrates consistent operational execution and potentially underestimation by analysts.
Strong Short-Term Momentum
The stock has shown significant positive performance over various short-term periods: +32.85% in 5 days, +27.44% in 1 month, and +22.78% in the current day's trading. This indicates strong current investor interest and buying pressure.
Bearish Points (7)
High P/E Ratio
The Price-to-Earnings (P/E) ratio on a trailing twelve-month (TTM) basis is 41.84. This is a high multiple, suggesting that the stock may be trading at a premium relative to its current earnings, potentially limiting upside or increasing downside risk.
Slowing Revenue Growth
Annual revenue growth has shown a downward trend, from 23.4% in 2021 to 17.0% in 2024 (estimated based on Q4 data). This deceleration could indicate market maturity or increasing competitive pressures.
Calendar
July 2025
24
Next Earnings Date
H: $1.70
A: $1.67
L: $1.65
H: 789.00M
A: 786.60M
L: 785.00M
July 2025
30
Ex-Dividend Date
August 2025
6
Next Dividend Date
Profile
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Seasonals
Price Target
291.01 USD
The 39 analysts offering 1 year price forecasts for WST have a max estimate of 350.00 and a min estimate of 245.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in pharmaceutical glass primary packaging, drug delivery systems, and contract manufacturing services. Highly similar business model to WST.
Weight: 97
Major global competitor in pharmaceutical packaging (glass and plastic), drug delivery devices (e.g., pre-fillable syringes, cartridges, auto-injectors), and medical plastic systems.
Weight: 95
Global leader in dispensing solutions for pharmaceutical, beauty, food, and beverage markets; significant overlap in pharmaceutical drug delivery devices.
Weight: 93
Major medical technology company with a strong presence in medication management solutions, pre-fillable syringes, and drug delivery systems, often integrating with packaging components like WST's.